News & Updates

Show Multimedia Only
Real-world data in Japan: 1L/2L palbociclib-ET effective in HR-positive/HER2-negative advanced breast cancer

Real-world data in Japan: 1L/2L palbociclib-ET effective in HR-positive/HER2-negative advanced breast cancer

13 May 2024